Industry ยท Oct 2026
Medical Device stocks ranked by gap to the model's fair value
Faircurve's model values 29 medical device stocks. 21 of them are ranked below by the gap between the model's fair value and the last close, as of 31 Oct 2026: 5 read as Undervalued, 15 as Fairly valued and 1 as Overvalued. The median gap across the ranked names is +1.0%. The widest gaps above the price are ENOV (+27.0%), ALGN (+24.1%), CTKB (+17.8%). The widest below it are SYK (-15.0%), EW (-13.9%), NEOG (-13.5%).
Valuations as of . Prices are the closes of 3 Nov 2026. The gap is the model's fair value against the price: a positive gap means the fair value is above the price. It states what the model concluded, not where the price goes next.
The ranking
| Rank | Company | Last close | Model fair value | Gap | Model verdict | Quality score | Market value |
|---|---|---|---|---|---|---|---|
| 1 | ENOV Enovis Corporation | $20.89 | $26.53 | +27.0% | Undervalued | 54 | $1.1B |
| 2 | ALGN Align Technology, Inc. | $151.58 | $188.05 | +24.1% | Undervalued | 75 | $10.6B |
| 3 | CTKB Cytek Biosciences, Inc. | $5.96 | $7.02 | +17.8% | Undervalued | 51 | $797M |
| 4 | PODD Insulet Corp. | $154.86 | $178.47 | +15.2% | Undervalued | 70 | $10.4B |
| 5 | GMED Globus Medical, Inc. | $79.58 | $91.57 | +15.1% | Undervalued | 78 | $10.5B |
| 6 | BRKR Bruker Corporation | $56.50 | $63.61 | +12.6% | Fairly valued | 46 | $8.7B |
| 7 | LIVN LivaNova PLC | $79.90 | $88.46 | +10.7% | Fairly valued | 66 | $4.3B |
| 8 | BSX Boston Scientific Corporation | $43.50 | $47.54 | +9.3% | Fairly valued | 61 | $60.8B |
| 9 | ZBH Zimmer Biomet Holdings, Inc. | $97.06 | $105.50 | +8.7% | Fairly valued | 41 | $18.0B |
| 10 | GEHC GE HealthCare Technologies Inc. | $80.66 | $81.91 | +1.5% | Fairly valued | 49 | $34.6B |
| 11 | DXCM DexCom, Inc. | $82.97 | $83.81 | +1.0% | Fairly valued | 74 | $31.1B |
| 12 | ABT Abbott Laboratories | $109.40 | $109.39 | 0.0% | Fairly valued | 58 | $183.8B |
| 13 | HAE Haemonetics Corporation | $120.28 | $117.17 | -2.6% | Fairly valued | 70 | $5.4B |
| 14 | ITGR Integer Holdings Corporation | $126.55 | $119.02 | -6.0% | Fairly valued | 43 | $4.3B |
| 15 | MDT Medtronic Plc | $98.88 | $92.90 | -6.0% | Fairly valued | 50 | $123.5B |
| 16 | BIO Bio-Rad Laboratories, Inc. | $374.91 | $350.46 | -6.5% | Fairly valued | 38 | $10.0B |
| 17 | PEN Penumbra, Inc. | $320.02 | $291.62 | -8.9% | Fairly valued | 64 | $12.6B |
| 18 | UFPT UFP Technologies, Inc. | $280.32 | $253.80 | -9.5% | Fairly valued | 74 | $2.2B |
| 19 | NEOG Neogen Corporation | $12.10 | $10.47 | -13.5% | Fairly valued | 26 | $2.6B |
| 20 | EW Edwards Lifesciences Corporation | $95.19 | $81.97 | -13.9% | Overvalued | 59 | $53.0B |
| 21 | SYK Stryker Corporation | $310.55 | $264.06 | -15.0% | Fairly valued | 55 | $111.9B |
The Global Pulse
Faircurve's market note, in your inbox each market day
The Global Pulse is Faircurve's note after each US session: what moved, in plain words. No account needed.
Valued but not ranked
These 8 names are valued but not ranked, for one of four reasons: the model grades the evidence as low or has not graded it yet, the inputs are under review, the gap is wider than 60%, or the valuation is more than three weeks old. The numbers are shown for reference.
| Company | Last close | Model fair value | Gap | Why it is not ranked | Quality score | Market value |
|---|---|---|---|---|---|---|
| AHCO AdaptHealth Corp. | $6.28 | $5.97 | -4.9% | Low evidence grade | 37 | $792M |
| AORT Artivion, Inc. | $23.71 | $21.20 | -10.6% | Low evidence grade | 50 | $1.1B |
| CNMD CONMED Corporation | $47.23 | $58.55 | +24.0% | Low evidence grade | 61 | $1.3B |
| GKOS Glaukos Corporation | $233.04 | $220.17 | -5.5% | Data under review | 54 | $14.1B |
| IART Integra LifeSciences Holdings Corporation | $13.63 | $9.30 | -31.8% | Low evidence grade | 57 | $992M |
| INSP Inspire Medical Systems, Inc. | $61.90 | $68.30 | +10.3% | Low evidence grade | $2.0B | |
| TMDX TransMedics Group, Inc. | $67.34 | $78.59 | +16.7% | Low evidence grade | 53 | $2.3B |
| TNDM Tandem Diabetes Care, Inc. | $17.65 | $19.14 | +8.4% | Low evidence grade | 51 | $1.3B |